By Market & Region

SHERIDAN, WYOMING – May 11, 2025 – Dentsply Sirona, in partnership with the American Association for Dental, Oral and Craniofacial Research (AADOCR), has officially announced the winners of the 2025 Student Competition for Advancing Dental Research and its Application (SCADA) Awards. Unveiled during the Opening Ceremonies of the 54th AADOCR Annual Meeting in New York, the awards spotlight student-led research poised to shape the future of oral healthcare innovation.

Highlighting Student Research Excellence in Dental Science

The SCADA Awards, a globally recognized platform for emerging dental researchers, continue to elevate promising talent within clinical, public health, basic, and translational science disciplines. This year’s winners were selected from top-tier dental schools across the United States and honored for their research addressing key challenges and advancements in dentistry.

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.

Strong Financial Performance in Q1 2025

For the first quarter of 2025, LivaNova recorded total revenue of $316.9 million, a 7.4% increase compared to the same period in 2024. On a constant-currency basis, revenue grew by 8.9%, with organic revenue expanding by 10.4%. Key drivers of growth included strong demand in the Cardiopulmonary and Neuromodulation segments, as well as increased sales from the Essenz™ Perfusion System and cardiopulmonary consumables.

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a leading global medical technology company, has announced 12-month top-line data from its OSPREY clinical trial. The study demonstrates promising results for the aura6000™ System, an investigational device designed to treat moderate to severe obstructive sleep apnea (OSA). The data highlights sustained improvements in key health metrics, positioning the aura6000™ as a potential breakthrough in OSA management.

Strong Results from 12-month OSPREY Data

The OSPREY trial's 12-month data shows significant improvements for patients receiving the aura6000™ System, demonstrating the effectiveness of proximal hypoglossal nerve stimulation (p-HGNS) in managing OSA. The results confirm the system’s potential as a long-term solution for patients with moderate to severe cases who have previously struggled with conventional treatments.

Key highlights from the study include:

SHERIDAN, WYOMING – May 09, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading provider of musculoskeletal solutions, has announced its financial results for the first quarter of 2025. The company reported worldwide net sales of $598.1 million, reflecting a 1.4% decrease year-over-year, primarily driven by a slowdown in Enabling Technology deal closures and temporary supply chain disruptions. Despite these challenges, Globus Medical saw notable growth in its core U.S. spine business and remains optimistic about its future prospects.

SHERIDAN, WYOMING – May 9, 2025 – Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions industry, has reported its financial results for the first quarter of 2025. Despite a slight dip in global net sales, the company remains confident in its ability to drive long-term growth and innovation. The results reflect challenges faced in certain areas, including slower deal closures in Enabling Technology, but also showcase the company’s strong positioning in the U.S. spine business.

SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.

SHERIDAN, WYOMING – May 8, 2025 – Invacare is proud to announce the launch of its global fundraiser, Move For Mobility 2025, which aims to provide life-changing wheelchairs to individuals in need around the world. The initiative brings together Invacare employees, ambassadors, clients, and partners in a worldwide effort to raise awareness and funds for the Free Wheelchair Mission, an organization committed to delivering wheelchairs at no cost to people with disabilities in remote communities.

A Strong Partnership with Free Wheelchair Mission

Since its inception, Invacare has partnered with Free Wheelchair Mission, a humanitarian non-profit organization, to help deliver mobility solutions to underserved populations globally. This year marks the sixth year of this partnership, with Invacare contributing its engineering, testing, and distribution expertise to help create durable and effective wheelchairs.

SHERIDAN, WYOMING – May 8, 2025 – SEALPAC is set to spotlight its new A6max traysealer at IFFA 2025, presenting a game-changing innovation in automated packaging under its #SealingTheFuture campaign. Designed to meet evolving industry demands around sustainability, efficiency, and product diversity, the A6max highlights the universal versatility of SEALPAC’s Amax-series and marks a strategic leap forward for food producers across traditional and alternative protein segments.

Operational Excellence for a Dynamic Market

The SEALPAC A6max is engineered to deliver maximum process reliability from denesting to sealing, ensuring high-quality output even at elevated production speeds. It’s built to address the operational pressures of modern food manufacturing, offering:

SHERIDAN, WYOMING – May 8, 2025 – SEALPAC has officially introduced its groundbreaking F-series thermoformer at IFFA 2025, positioning the new machine as a transformative innovation in industrial packaging. Purpose-built to redefine thermoforming standards, the F-series integrates intelligent automation, rapid format adaptability, and sustainability-focused engineering—making it a strategic asset for forward-looking food manufacturers and processors.

Rethinking Thermoforming for Modern Industry Needs

Designed entirely from the ground up, the SEALPAC F-series represents a radical departure from traditional thermoformer models. Leveraging decades of German engineering expertise, the F-series has been engineered for maximum operational flexibility, precision processing, and intuitive control.

SHERIDAN, WYOMING – May 8, 2025 – In a strategic move to combat skilled labor shortages while preserving premium product quality, Austrian retailer Kaufhaus Hubmann has integrated SEALPAC’s semi-automatic M-Flex traysealer into its deli department operations. The initiative not only safeguards the company’s renowned service standards but also represents a significant leap toward operational efficiency and sustainable packaging in food retail.

A Scalable Solution to Industry-Wide Staffing Challenges

Faced with rising difficulties in staffing deli counters—an issue echoed across the retail food sector—Kaufhaus Hubmann sought a solution that could maintain its commitment to freshness and service. The answer came in the form of SEALPAC’s M-Flex traysealer, which now allows the company to deliver freshly cut deli products multiple times a day, regardless of employee availability.

SHERIDAN, WYOMING – May 8, 2025 – Mölnlycke Health Care has reiterated its unwavering support for the Wound Care Collaborative Community (WCCC) initiative, which seeks to develop a standardized pre-clinical testing framework for wound dressings. The collaboration aims to drive improvements in patient care by ensuring more consistent and clinically relevant product evaluations across the wound care industry.

The initiative brings together clinicians, materials management teams, regulators, and industry experts with a shared vision: to refine wound dressing standards that better reflect real-world needs. Mölnlycke Health Care has been a steadfast partner in this project, working with leading players in the wound care sector to enhance product development and improve patient outcomes.

SHERIDAN, WYOMING – May 8, 2025 – The 9th AVF Summit – powered by VertiFarm – will bring the global vertical farming community together in Munich this September, uniting top innovators, researchers, and industry leaders under the theme “Global Food Challenges: Vertical Farming as a Catalyst for Innovation & Climate Action.” As climate volatility and global food insecurity intensify, the event signals a strategic inflection point for Controlled Environment Agriculture (CEA) and vertical farming as scalable, sustainable solutions.

Driving Innovation Amid Climate and Resource Pressures

SHERIDAN, WYOMING – May 8, 2025 – swissQprint showcased a compelling suite of innovations at the Fespa Global Print Expo 2025, with its Generation 5 flatbed printers commanding attention among industry leaders and buyers alike. The Swiss manufacturer demonstrated its continued commitment to productivity, customization, and high-margin application potential across global markets.

Next-Generation Flatbed Solutions Redefine Quality and Speed

At the heart of swissQprint’s presentation was the new Generation 5 flatbed printer line, which has been shipping to customers on all five continents since January. Engineered with a modular architecture, the trio of models—Kudu, Nyala, and Impala—offers enhanced flexibility and application diversity, built on a completely redesigned foundation.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care has kicked off fiscal year 2025 with robust financial performance, driven by strong organic revenue growth and significant operational efficiencies. The world’s leading provider of dialysis products and services posted a 5% increase in organic revenue, highlighting continued operational improvements in both its Care Enablement and Care Delivery segments.

Strong Financial Results in Q1 2025

In the first quarter of 2025, Fresenius Medical Care achieved notable revenue growth, with total sales rising 3% year-on-year, and organic growth accounting for a 5% increase. The company’s total revenue for Q1 amounted to EUR 4,881 million. Despite the challenges posed by a severe flu season, which impacted dialysis treatment volumes in the U.S., the company demonstrated resilience through its diversified service offerings and strategic operational improvements.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care (FME) celebrates a major milestone as its dialysis center in Sokolov, Czech Republic, marks its 40th anniversary. With a commitment to providing high-quality care, NephroCare, under the FME brand, continues to serve around 100 dialysis patients, offering specialized nephrological services and cutting-edge dialysis treatments.

Pioneering Dialysis Care in the Czech Republic

The Sokolov dialysis center, located in the western Bohemia region, was founded in 1985 and has been at the forefront of chronic kidney disease treatment in the Czech Republic. From the beginning, the center’s innovative approach and dedication to patient well-being have set it apart.

SHERIDAN, WYOMING – May 8, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) today confirmed that all proposals presented at its Annual General Meeting of Shareholders (AGM) 2025 have been approved, strengthening the company’s governance structure and positioning its leadership team to execute on long-term strategic objectives in the health technology sector.

Shareholder backing of key appointments and re-appointments underscores continued investor confidence in Philips’ strategic direction. This includes the re-appointment of seasoned leaders Indra Nooyi and Chua Sock Koong to the Supervisory Board, the addition of global health tech expert Bob White, and the renewed mandate for Marnix van Ginneken as a member of the Board of Management.

Leadership Reinforcement for Strategic Execution

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

Robust Financial Growth and Increased Efficiency

In a year marked by rising costs and market volatility, B. Braun’s fiscal year 2024 results showcase the company’s ability to drive growth and improve profitability. The company’s sales surged to 9.1 billion euros, up from 8.8 billion euros the previous year. At constant exchange rates, this represents a notable 6.8% increase, aligning with B. Braun’s long-term growth target of 5-7%.

Key highlights from the 2024 fiscal year include:

SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.

Key Appointments and Re-elections

At the 2025 AGM, shareholders re-elected F. Michael Ball as Chair of the Board of Directors, alongside several other members who stood for re-election. This includes Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, and Dieter Spälti. These appointments ensure the continued leadership and strategic direction of Alcon for the upcoming term.

SHERIDAN, WYOMING – May 8, 2025 – Alcon, the global leader in eye care, has announced its continued partnership with the Association for Research in Vision and Ophthalmology (ARVO) for the Eye Pitch live event, set to take place at the ARVO 2025 annual meeting in Salt Lake City, Utah, on May 3, 2025. This event will serve as a platform for entrepreneurs and researchers within the ophthalmic community to present groundbreaking ideas aimed at transforming eye care.

The Eye Pitch event allows ARVO members to pitch their innovative drug, device, or research proposals to a distinguished panel from both ARVO and the Alcon Seed Fund. The competition aims to spotlight early- and mid-stage innovations in the ophthalmic field, offering participants the chance to advance to the next phase of investment.

A Platform for Innovation

SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.

The Elecsys PRO-C3 test leverages Roche’s cobas® analyzers, delivering results in just 18 minutes, offering a swift and reliable diagnostic method. This new technology promises to significantly improve patient outcomes by enabling earlier identification of liver fibrosis, particularly in those affected by MASLD, and guiding timely treatment interventions.